Autolus Therapeutics (AUTL) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $1.60, -6.98% vs the prior close of $1.72.
- Volume 2.35M shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AUTL slides 7.0% to $1.60, a 1-month low. Closed at $1.60, -6.98% vs the prior close of $1.72. Day range $1.59–$1.74, opened at $1.74.
AUTL daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AUTL slides 7.0% to $1.60, a 1-month low
- Closed at $1.60, -6.98% vs the prior close of $1.72. Day range $1.59–$1.74, opened at $1.74.
- Volume was 2.35M shares, 1.1x its 50-day average of 2.13M.
- Price is -21.7% vs its 50-day average ($2.04) and -4.5% vs its 200-day average ($1.68).
- 52-week range $1.17–$2.58; today's close sits at 30% of that range, 38.0% below the 52-week high.
Oct 15, 2026 — AUTL rises 1.8% to $1.72
- Closed at $1.72, +1.78% vs the prior close of $1.69. Day range $1.68–$1.74, opened at $1.70.
- Volume was 1.49M shares, 0.7x its 50-day average of 2.13M.
- Price is -16.1% vs its 50-day average ($2.05) and +2.5% vs its 200-day average ($1.68).
- 52-week range $1.17–$2.58; today's close sits at 39% of that range, 33.3% below the 52-week high.
Oct 14, 2026 — AUTL jumps 4.3% to $1.69
- Closed at $1.69, +4.32% vs the prior close of $1.62. Day range $1.60–$1.70, opened at $1.61.
- Volume was 2.59M shares, 1.2x its 50-day average of 2.16M.
- Price is -17.7% vs its 50-day average ($2.05) and +0.7% vs its 200-day average ($1.68).
- 52-week range $1.17–$2.58; today's close sits at 37% of that range, 34.5% below the 52-week high.
Oct 13, 2026 — AUTL slides 6.9% to $1.62, a 1-month low
- Closed at $1.62, -6.90% vs the prior close of $1.74. Day range $1.60–$1.74, opened at $1.74.
- Volume was 2.41M shares, 1.0x its 50-day average of 2.38M.
- Price is -21.3% vs its 50-day average ($2.06) and -3.5% vs its 200-day average ($1.68).
- 52-week range $1.17–$2.58; today's close sits at 32% of that range, 37.2% below the 52-week high.
Oct 12, 2026 — AUTL slides 3.9% to $1.74, a 1-month low
- Closed at $1.74, -3.87% vs the prior close of $1.81. Day range $1.74–$1.82, opened at $1.82.
- Volume was 1.05M shares, 0.4x its 50-day average of 2.38M — lighter than usual.
- Price is -15.7% vs its 50-day average ($2.06) and +3.7% vs its 200-day average ($1.68).
- 52-week range $1.17–$2.58; today's close sits at 40% of that range, 32.6% below the 52-week high.
Oct 9, 2026 — AUTL rises 2.3% to $1.81
- Closed at $1.81, +2.26% vs the prior close of $1.77. Day range $1.73–$1.82, opened at $1.75.
- Volume was 1.48M shares, 0.6x its 50-day average of 2.38M.
- Price is -12.1% vs its 50-day average ($2.06) and +7.9% vs its 200-day average ($1.68).
- 52-week range $1.17–$2.58; today's close sits at 45% of that range, 29.8% below the 52-week high.
Oct 8, 2026 — AUTL dips 2.2% to $1.77, a 1-month low
- Closed at $1.77, -2.21% vs the prior close of $1.81. Day range $1.72–$1.78, opened at $1.78.
- Volume was 1.60M shares, 0.7x its 50-day average of 2.37M.
- Price is -13.8% vs its 50-day average ($2.05) and +5.5% vs its 200-day average ($1.68).
- 52-week range $1.17–$2.58; today's close sits at 42% of that range, 31.4% below the 52-week high.
Oct 7, 2026 — AUTL rises 1.1% to $1.81
- Closed at $1.81, +1.12% vs the prior close of $1.79. Day range $1.73–$1.81, opened at $1.78.
- Volume was 1.55M shares, 0.7x its 50-day average of 2.34M.
- Price is -11.5% vs its 50-day average ($2.05) and +7.9% vs its 200-day average ($1.68).
- 52-week range $1.17–$2.58; today's close sits at 45% of that range, 29.8% below the 52-week high.
Oct 6, 2026 — AUTL dips 2.2% to $1.79
- Closed at $1.79, -2.19% vs the prior close of $1.83. Day range $1.76–$1.87, opened at $1.84.
- Volume was 1.68M shares, 0.7x its 50-day average of 2.32M.
- Price is -12.2% vs its 50-day average ($2.04) and +6.8% vs its 200-day average ($1.68).
- 52-week range $1.17–$2.58; today's close sits at 44% of that range, 30.6% below the 52-week high.
Oct 5, 2026 — AUTL rises 2.8% to $1.83
- Closed at $1.83, +2.81% vs the prior close of $1.78. Day range $1.75–$1.86, opened at $1.78.
- Volume was 2.52M shares, 1.1x its 50-day average of 2.29M.
- Price is -10.0% vs its 50-day average ($2.03) and +9.3% vs its 200-day average ($1.67).
- 52-week range $1.17–$2.58; today's close sits at 47% of that range, 29.1% below the 52-week high.
Oct 2, 2026 — AUTL slides 3.8% to $1.78, a 1-month low
- Closed at $1.78, -3.78% vs the prior close of $1.85. Day range $1.76–$1.88, opened at $1.85.
- Volume was 1.81M shares, 0.8x its 50-day average of 2.27M.
- Price is -12.1% vs its 50-day average ($2.02) and +6.4% vs its 200-day average ($1.67).
- 52-week range $1.17–$2.58; today's close sits at 43% of that range, 31.0% below the 52-week high.
AUTL latest news & SEC filings
Every SEC filing by or about AUTL in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 22, 2026 · Form EFFECT — EFFECT filing
EFFECT filing
Sep 22, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 15, 2026 · Form DEL AM — DEL AM filing
DEL AM filing
Sep 14, 2026 · Form S-3 — Shelf registration (S-3)
Shelf registration (S-3) — lets the company sell securities over time
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Piccina Cintia sold 6,713 shares at $2.34 (≈$15.71K) on Sep 2, 2026
- Piccina Cintia sold 6,713 shares at $2.34 (≈$15.71K) on Sep 2, 2026
- Piccina Cintia sold 6,713 shares at $2.34 (≈$15.71K) on Sep 2, 2026
- Piccina Cintia sold 6,713 shares at $2.34 (≈$15.71K) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 2, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 28, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $45.69M (prior year $20.92M) (+118.4% vs Jun 30, 2025)
- Net income: -$39.11M (prior year -$47.92M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.15 (prior year -$0.18) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
- Item 8.01 — Reported other events the company considers important.
Aug 3, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Jul 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade AUTL
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: May 14, 2026, Mar 27, 2026, Nov 12, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.05% (largest 7.0%). That is a volatile stock.
- Liquidity: about 1.68M shares (≈$2.69M) trade per day on average.
- 52-week position: $1.60 vs a range of $1.17–$2.58 (30% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 4 sales; latest: Cintia Piccina sold 6,713 shares on Sep 2, 2026.
- Latest filings: 10-Q Aug 11, 2026; 8-K Aug 11, 2026; 8-K Aug 3, 2026.
- Share count: 266.16M shares outstanding (Aug 10, 2026), +0.0% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
AUTL market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 1.74 | 1.74 | 1.59 | 1.60 | 2.35M |
| Oct 15, 2026 | 1.70 | 1.74 | 1.68 | 1.72 | 1.49M |
| Oct 14, 2026 | 1.61 | 1.70 | 1.60 | 1.69 | 2.59M |
| Oct 13, 2026 | 1.74 | 1.74 | 1.60 | 1.62 | 2.41M |
| Oct 12, 2026 | 1.82 | 1.82 | 1.74 | 1.74 | 1.05M |
| Oct 9, 2026 | 1.75 | 1.82 | 1.73 | 1.81 | 1.48M |
| Oct 8, 2026 | 1.78 | 1.78 | 1.72 | 1.77 | 1.60M |
| Oct 7, 2026 | 1.78 | 1.81 | 1.73 | 1.81 | 1.55M |
| Oct 6, 2026 | 1.84 | 1.87 | 1.76 | 1.79 | 1.68M |
| Oct 5, 2026 | 1.78 | 1.86 | 1.75 | 1.83 | 2.52M |
| Oct 2, 2026 | 1.85 | 1.88 | 1.76 | 1.78 | 1.81M |
| Oct 1, 2026 | 1.94 | 1.94 | 1.85 | 1.85 | 1.46M |
| Sep 30, 2026 | 1.88 | 1.99 | 1.87 | 1.94 | 1.16M |
| Sep 29, 2026 | 1.86 | 1.88 | 1.80 | 1.86 | 1.77M |
| Sep 28, 2026 | 1.82 | 1.89 | 1.79 | 1.86 | 1.40M |
| Sep 25, 2026 | 1.91 | 1.95 | 1.85 | 1.86 | 1.38M |
| Sep 24, 2026 | 1.95 | 1.97 | 1.88 | 1.91 | 1.82M |
| Sep 23, 2026 | 2.04 | 2.05 | 1.92 | 1.95 | 1.44M |
| Sep 22, 2026 | 1.96 | 2.08 | 1.94 | 2.03 | 1.57M |
| Sep 21, 2026 | 1.95 | 1.96 | 1.91 | 1.94 | 1.10M |
About Autolus Therapeutics
Autolus Therapeutics (AUTL) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in LONDON, United Kingdom. State of incorporation: United Kingdom. Fiscal year ends December 31. SEC CIK 1730463.
AUTL board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Robert Azelby | Director | Jul 1, 2026 |
| Michael W Bonney | Director | Jul 1, 2026 |
| Cynthia M Butitta | Director | Jul 1, 2026 |
| Linda Bain | Director | Jul 1, 2026 |
| John E Berriman | Director | Mar 18, 2026 |
| Robert Iannone | Director | Jul 1, 2026 |
| Christian Itin | Chief Executive Officer | Mar 18, 2026 |
| Elisabeth Leiderman | Director | Jul 1, 2026 |
| Martin Anton Pule | Director | Mar 18, 2026 |
| Madduri Ravin Rao | Director | Jul 1, 2026 |
| Ryan Richardson | Director | Jul 1, 2026 |
| William D Young | Director | Jul 1, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Robert Dolski | Chief Financial Officer | Mar 18, 2026 |
| Alex Driggs | SVP, Legal Affairs and GC | Mar 18, 2026 |
| Christian Itin | Chief Executive Officer | Mar 18, 2026 |
| Patrick Paul Mcilvenny | SVP Finance | Mar 18, 2026 |
| Miranda Suzette Neville | Chief Technology Officer | Mar 18, 2026 |
| Cintia Piccina | U.S. CCO & Country Gen Manager | Sep 3, 2026 |
| Alexander Swan | Chief Human Resources Officer | Mar 18, 2026 |
| Christopher Andrew Vann | Chief Operating Officer | Mar 18, 2026 |
| Matthias Will | Chief Development Officer | Mar 18, 2026 |
| Christopher Michael James Williams | Chief Business Officer | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Cintia Piccina | Sale | 6,713 | $2.34 |
| Sep 2, 2026 | Cintia Piccina | Sale | 6,713 | $2.34 |
| Sep 2, 2026 | Cintia Piccina | Sale | 6,713 | $2.34 |
| Sep 2, 2026 | Cintia Piccina | Sale | 6,713 | $2.34 |
AUTL financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $75.39M | $-287.53M | -1.08 | $-283.57M |
| Dec 31, 2024 | $10.12M | $-220.66M | -0.86 | $-206.27M |
| Dec 31, 2023 | — | $-208.38M | -1.20 | $-145.59M |
| Dec 31, 2022 | — | $-148.84M | -1.57 | $-112.31M |
| Dec 31, 2021 | — | $-142.10M | -1.97 | $-117.86M |
Latest balance sheet: total assets $493.23M, total liabilities $418.39M, cash $171.41M (as of Jun 30, 2026).
AUTL earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $2.33 |
| May 14, 2026 | 8-K Item 2.02 (results) | $1.59 |
| Mar 27, 2026 | 8-K Item 2.02 (results) | $1.21 |
| Nov 12, 2025 | 8-K Item 2.02 (results) | $1.36 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $2.15 |
| May 8, 2025 | 8-K Item 2.02 (results) | $1.35 |
| Mar 20, 2025 | 8-K Item 2.02 (results) | $1.67 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $3.33 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 17, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AUTL
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.